GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Durata Therapeutics Inc (FRA:DTA) » Definitions » 12-1 Month Momentum %

Durata Therapeutics (FRA:DTA) 12-1 Month Momentum % : N/A% (As of May. 05, 2024)


View and export this data going back to . Start your Free Trial

What is Durata Therapeutics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-05), Durata Therapeutics's 12-1 Month Momentum % is N/A%.

The industry rank for Durata Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

FRA:DTA's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -21.305
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Competitive Comparison of Durata Therapeutics's 12-1 Month Momentum %

For the Biotechnology subindustry, Durata Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Durata Therapeutics's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Durata Therapeutics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Durata Therapeutics's 12-1 Month Momentum % falls into.



Durata Therapeutics  (FRA:DTA) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Durata Therapeutics  (FRA:DTA) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Durata Therapeutics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Durata Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Durata Therapeutics (FRA:DTA) Business Description

Traded in Other Exchanges
N/A
Address
Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.

Durata Therapeutics (FRA:DTA) Headlines

No Headlines